MDxHealth, Inc.'s Confirmmdx DOCUMENT Validation Study Published In The Journal Of Urology

IRVINE, Calif. and HERSTAL, Belgium, May 8, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that results from DOCUMENT, a blinded, multicenter clinical validation study, substantiate that its ConfirmMDx® for Prostate Cancer test is a significant independent predictor of the risk for cancer on repeat biopsy. The accepted manuscript describing the study results is posted on the Journal of Urology (http://www.jurology.com/article/S0022-5347(14)03341-2/abstract) website and the data will be presented by principle investigator Alan Partin, MD, PhD, Professor and Chief of Urology at the James Buchanan Brady Urological Institute at Johns Hopkins School of Medicine, at the upcoming 2014 Annual Meeting of the American Urology Association (AUA) in Orlando, Florida.

Help employers find you! Check out all the jobs and post your resume.